Catalyst Pharmaceuticals Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Miami, FL USA
Total Funding:$15.1M
Industry:Pharma
Founded:2002
Lead Investor(s):Piper Jaffray & Co

Industry Ranking

Estimated Revenue & Financials

  • Catalyst Pharmaceuticals's estimated annual revenue is currently $5.2M per year.
  • Catalyst Pharmaceuticals received $57.5M in venture funding in November 2017.
  • Catalyst Pharmaceuticals's estimated revenue per employee is $76,853
  • Catalyst Pharmaceuticals's total funding is $15.1M.

Employee Data

  • Catalyst Pharmaceuticals has 68 Employees.
  • Catalyst Pharmaceuticals grew their employee count by 48% last year.
  • Catalyst Pharmaceuticals currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Biotest Pharmac...
$135.9M676N/AN/AN/A
Noven Pharmaceu...
N/A1058N/AN/AN/A
Benzer Pharmacy...
$9.2M46-4%N/AN/A
Knox Medical
$29.7M14812%N/AN/A
Anda,Inc
N/A319N/AN/AN/A
Ingenus Pharmac...
$33M1644%N/AN/A
BioPlus Special...
$53.9M26820%N/AN/A
AnazaoHealth Co...
$24.7M123N/AN/AN/A
Biorasi
$40.8M2030%N/AN/A
TherapeuticsMD
$16.1M363-16%N/AN/A
Missing a competitor? Contribute!?
Submit

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's Disorder. Catalyst's lead candidate, Firdapse® for the treatment of LEMS, has completed testing in a global, multi-center, double-blinded randomized pivotal Phase 3 trial resulting in positive top-line data and Catalyst has recently filed an NDA for this product seeking approval for its use as a treatment of LEMS and CMS. Firdapse® for the treatment of LEMS has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for LEMS and CMS. Firdapse® is the first and only European approved drug for symptomatic treatment in adults with LEMS. Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder and Tourette's Disorder. CPP-115 has been granted U.S. orphan drug designation for the treatment of infantile spasms by the FDA and has been granted E.U. orphan medicinal product designation for the treatment of West Syndrome by the European Commission. In addition, Catalyst is developing a generic version of Sabril® (vigabatrin).

keywords:Biotechnology,Healthcare,Pharmaceuticals

68

Number of Employees

$5.2M

Revenue (est)

1

Current Jobs

48%

Employee Growth %

$15.1M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Executive Contacts

NameTitleEmail
Adriana ManariManager, Clinical TrialEmail Available
Dan BrennanChief Commercial OfficerEmail Available
David CaponeraVP Patient Engagement & Access SupportEmail Available
Isabel NunezExecutive Assistant To Chief Executive OfficerEmail Available
Ismaris BouchardDirector Of Financial ReportingEmail Available
Jeff GilbertRegional Account ManagerEmail Available
Desiree HollandsworthDirector, Marketing And Commercial Operations
Amy GroverDirector of Patient AdvocacyEmail Available
Kay ForsheeDirector of Revenue ManagementEmail Available
Brian ElsberndChief Legal And Compliance OfficerEmail Available

Catalyst Pharmaceuticals News

09/03/2019 - Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX): It's A Good ...

Intraday Trading of Catalyst Pharmaceuticals, Inc.: If one intends to pursue a career as a trader, then one must understand and choose between ...

08/28/2019 - Catalyst Pharmaceuticals to Participate in the 14th Annual Citi ...

CORAL GABLES, Fla., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical ...

09/03/2019 - Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 1 ...

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)'s share price reached a new 52-week high on Friday . The stock traded as high as $6.69 and ...

Catalyst Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2009-10-05$4.0MUndisclosedArticle
2010-08-09$1.5MUndisclosedArticle
2012-05-31$4.0MUndisclosedCowen and Company LLCArticle
2012-08-29$6.0MUndisclosedRoth Capital PartnersArticle
2014-04-04$28.7MUndisclosedArticle
2014-04-09$26.8MUndisclosedPiper Jaffray & CoArticle
2015-02-10$34.7MUndisclosedPiper Jaffray & CoArticle
2017-11-29$57.5MUndisclosedPiper Jaffray & CoArticle

Catalyst Pharmaceuticals Executive Hires

DateNameTitleReference
2005-01-11Jack WeinsteinCFOArticle
2006-09-08Charles W. GorodetzkyCMOArticle
2007-04-05Steven R. MillerVP Pharmaceutical DevelopmentArticle
2008-03-06Patrick KennyDir Corporate Clinical ComplianceArticle
2009-10-14Steven R. MillerChief Scientific OfficerArticle
2011-11-15Richard P. RiegerVP Commercial OperationsArticle
2013-03-06Bernardino MosqueraVP Clinical OperationsArticle
2014-09-05David D. MuthEVP Corporate DevelopmentArticle
2014-10-29David J. CaponeraVP Patient Advocacy and ReimbursementArticle
2015-01-06David D. MuthEVP/Chief Commercial OfficerArticle
2016-02-29Brian ElsberndSVP Legal & ComplianceArticle
2018-06-14Daniel BrennanChief Commercial OfficerArticle
2018-08-07Jason Jamessvp Commercial Operations & AnalyticsArticle
2018-08-21Stanley IyaduraiVP Clinical DevelopmentArticle